Abstract:Alzheimer's disease (AD) is a progressive neurodegenerative disorder that destroys patient memory and cognition, communication ability with the social environment and the ability to carry out daily activities. Despite extensive research into the pathogenesis of AD, a neuroprotective treatment - particularly for the early stages of disease - remains unavailable for clinical use. In this review, we advance the suggestion that lipoic acid (LA) may fulfil this therapeutic need. A naturally occurring cofactor for the mitochondrial enzymes pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, LA has been shown to have a variety of properties which can interfere with the pathogenesis or progression of AD. For example, LA increases acetylcholine (ACh) production by activation of choline acetyltransferase and increases glucose uptake, thus supplying more acetyl-CoA for the production of ACh. LA chelates redox-active transition metals, thus inhibiting the formation of hydroxyl radicals and also scavenges reactive oxygen species (ROS), thereby increasing the levels of reduced glutathione. In addition, LA down-regulates the expression of redox-sensitive pro-inflammatory proteins including TNF and inducible nitric oxide synthase. Furthermore, LA can scavenge lipid peroxidation products such as hydroxynonenal and acrolein. In human plasma, LA exists in an equilibrium of free and plasma protein bound form. Up to 150 muM, it is bound completely, most likely binding to high affinity fatty acid sites on human serum albumin, suggesting that one large dose rather than continuous low doses (as provided by "slow release" LA) will be beneficial for delivery of LA to the brain. Evidence for a clinical benefit for LA in dementia is yet limited. There are only two published studies, in which 600 mg LA was given daily to 43 patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of up to 48 months. Whereas the improvement in patients with moderate dementia was not significant, the disease progressed extremely slowly (change in ADAScog: 1.2 points=year, MMSE: -0.6 points=year) in patients with mild dementia (ADAScog<15). Data from cell culture and animal models suggest that LA could be combined with nutraceuticals such as curcumin, (-)-epigallocatechin gallate (from green tea) and docosahexaenoic acid (from fish oil) to synergistically decrease oxidative stress, inflammation, Abeta levels and Abeta plaque load and thus provide a combined benefit in the treatment of AD.

Role of Lipoic Acid in Multiple Sclerosis

Α-Lipoic Acid Treatment Improves Vision-Related Quality of Life in Patients with Dry Age-Related Macular Degeneration.

Neuroprotective Effects of Α-Lipoic Acid on Long-Term Experimental Autoimmune Encephalomyelitis.

Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease

Lipoic acid protects dopaminergic neurons in LPS-induced model of Parkinson’s disease

Lipoic Acid Protects Dopaminergic Neurons in LPS-induced Parkinson's Disease Model.

Neuroprotective Effect of α-Lipoic Acid against Aβ25-35-Induced Damage in BV2 Cells

Lanthionine ketimine ester provides benefit in a mouse model of multiple sclerosis

Propionic Acid Impact on Multiple Sclerosis: Evidence and Challenges

α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review

Antioxidant and Anti-inflammatory Effects of α-Lipoic Acid on Lipopolysaccharide-induced Oxidative Stress in Rat Kidney

Lipoic Acid Protected PC12 Cells from Oxidative Stress-induced Damage by inhibiting the NF-κB-iNOS-NO Signal Pathway

Lysophosphatidic acid receptor 1 influences disease severity in a mouse model of multiple sclerosis

Alpha-lipoic Acid: An Antioxidant with Anti-Aging Properties for Disease Therapy

Effects of lipoic acid on the redox state and macro-vascular complications in diabetic mice

Novel Nano-Carriers with N-formylmethionyl-leucyl-phenylalanine-modified Liposomes Improve Effects of C16-angiopoietin 1 in Acute Animal Model of Multiple Sclerosis.

[Effects of Lipoic Acid on Cytokines and Chemokines in Astrocytes Stimulated with Lipopolysaccharide].

Protective Role of High-Density Lipoprotein in Multiple Sclerosis

Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits

Linoleic Acid Alleviates Lipopolysaccharide Induced Acute Liver Injury via Activation of Nrf2

Review of lipoic acid: from a clinical therapeutic agent to various emerging biomaterials